Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.53 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077568 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL27398355 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL31291173 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL1039828 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL3487114 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL23963850 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL19104359 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL5580067 | 0.98 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL12107793 | 0.95 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL30195173 | 0.95 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119098-A1 | LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | SIRIUS THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| EP-3500581-A1 | POLYNUCLEOTIDE CONSTRUCTS | Solstice Biologics, Ltd. (IE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035380-A1 | POLYNUCLEOTIDE CONSTRUCTS | SOLSTICE BIOLOGICS, LTD. (IE) | 2018-02-22 | — | — | WO | disclosed |
| US-20180021454-A1 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-01-25 | — | — | US | disclosed |
| US-9763995-B2 | Polymer conjugates of protegrin peptides | NEKTAR THERAPEUTICS (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20110206633-A1 | POLYMER CONJUGATES OF CD-NP PEPTIDES | Nektar Therapectics (US) | 2011-08-25 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| EP-1590317-B1 | ENANTIOMER-PURE (4S,8S)- AND (4R, 8R)-4-P-NITROBENZYL-8-METHYL-3, 6, 9-TRIAZA- SP 3 /sp N, SP 6 /SP N, SP 9 /SP N-TRICARBOXYMETHYL-1, 11-UNDECANOIC ACID AND DERIVATIVES THEREOF, METHOD FOR PRODUCING THEM, AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| WO-2004108678-A1 | (1,2,3,4-TETRAHYDROQUINOLIN-8-YL)-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040220231-A1 | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity | LEE LEN F (US) | 2004-11-04 | — | — | US | disclosed |
| US-6794396-B2 | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity | PHARMACIA CORPORATION | 2004-09-21 | — | — | US | disclosed |
| US-20040038939-A1 | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity | PHARMACIA CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-6605624-B1 | Preventing and/or treating atherosclerosis and other coronary artery diseases | PHARMACIA CORPORATION | 2003-08-12 | — | — | US | disclosed |
| WO-1999041237-A1 | SUBSTITUTED PYRIDINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206633-A1 | POLYMER CONJUGATES OF CD-NP PEPTIDES | CD63, CLSPN, LNPEP | EHMT2 4657/4885EHMT1 4594/4885APOBEC3G 2487/4885 |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | EHMT2 3919/4885EHMT1 4358/4885APOBEC3G 234/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | EHMT2 4337/4885EHMT1 4185/4885APOBEC3G 2236/4885 |
| US-11981703-B2 | Polynucleotide constructs | PHAX, CPSF6, RNGTT | EHMT2 4639/4885EHMT1 4841/4885APOBEC3G 1360/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | EHMT2 4311/4885EHMT1 4171/4885APOBEC3G 2475/4885 |
| US-20040038939-A1 | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity | CETP, CES1, MTTP | EHMT2 4145/4885EHMT1 3628/4885APOBEC3G 4577/4885 |
| US-20040220231-A1 | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | EHMT2 4147/4885EHMT1 3943/4885APOBEC3G 4517/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | EHMT2 2267/4885EHMT1 2192/4885APOBEC3G 2021/4885 |
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | PHAX, CPSF6, RNGTT | EHMT2 4639/4885EHMT1 4841/4885APOBEC3G 1360/4885 |
| US-20180021454-A1 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | CD47, CD44, FURIN | EHMT2 3563/4885EHMT1 3717/4885APOBEC3G 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.